Welcome to our dedicated page for Becton, Dickinson and Co. news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton, Dickinson and Co. stock.
Becton, Dickinson and Company (BD) (NYSE: BDX) is a global medical technology firm committed to advancing healthcare through the development, manufacture, and sale of a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. Established in 1897, BD's mission is to enhance medical discovery, diagnostics, and care delivery. The company's extensive product portfolio serves healthcare institutions, physicians, life science researchers, and others across the globe.
BD is noted for being the world’s largest manufacturer and distributor of medical surgical products such as needles, syringes, and sharps-disposal units. The company also excels in producing pre-filled devices, diagnostic instruments, and reagents. Furthermore, BD offers sophisticated flow cytometry and cell-imaging systems. BD Medical represents nearly half of the company's total business, while BD Life Sciences and BD Interventional contribute 27% and 24% of the 2023 revenue, respectively. Impressively, international revenue accounts for 43% of the company's business.
Recent achievements and projects underscore BD's commitment to innovation and sustainability. The company recently collaborated with health care institutions in Denmark to explore recycling used blood collection tubes, achieving significant environmental advancements without compromising safety or quality.
In a pivotal development, BD announced the global commercial release of new cell sorters, enabling researchers in fields such as cell biology, cancer research, and immunology to gain new insights. The BD FACSDiscover™ S8 Cell Sorters incorporate groundbreaking technologies like BD CellView™ Image Technology and BD SpectralFX™ Technology, significantly enhancing real-time imaging and spectral flow cytometry.
BD also reported robust financial performance for the second quarter of fiscal 2024, highlighting strong operating margins and cash flow. This success led to an optimistic outlook and an increased earnings guidance, demonstrating the company’s resilience and strategic execution.
Further solidifying its market position, BD is set to acquire Edwards Lifesciences' Critical Care product group for $4.2 billion. This acquisition expands BD’s portfolio in smart connected care solutions, leveraging advanced AI algorithms for better patient outcomes and adding significant value to its operations.
With a presence in almost every country and a workforce of over 70,000 employees, BD remains dedicated to advancing the world of health. The company works closely with customers and partners globally to address complex health challenges, enhance clinical outcomes, and expand access to healthcare.
BD (NYSE: BDX) has launched the BD Prevue™ II System, an advanced ultrasound device aimed at improving peripheral IV placement. This technology addresses challenges in IV access by offering real-time needle depth indicators and compatibility with BD Cue™ Needle Tracking-enabled catheters. Studies suggest that leveraging ultrasound and needle tracking can enhance the safety and efficiency of vascular access procedures, which affect over 90% of hospitalized patients. The system is designed with user-friendly features to facilitate quick adoption by clinicians. BD continues to pursue its vision of a 'One-Stick Hospital Stay' to minimize patient discomfort and enhance IV therapy effectiveness.
BD (NYSE: BDX) announced that it will report its financial results for the second quarter of fiscal year 2023 on May 4, 2023. The results will be available at approximately 6:30 a.m. ET and will include summary financial information for the quarter ending March 31, 2023. An audio webcast hosted by management will follow at 8 a.m. ET on the same day, discussing financial results, operations, and strategic updates. For access, visit BD's investor relations website. BD is recognized as a global leader in medical technology, committed to enhancing healthcare delivery.
On April 3, 2023, Becton, Dickinson and Company (NYSE: BDX) announced the appointment of Michelle Quinn as Executive Vice President and General Counsel, effective April 1. Quinn, who joined BD in 2019, previously served as Acting General Counsel and Senior Vice President. She will lead the Law Group and report to Tom Polen, CEO. Quinn's extensive experience in healthcare legal functions is expected to support BD's business strategies and governance initiatives. She holds a Juris Doctor from Villanova University and a Bachelor of Arts from Colgate University.
BD (NYSE: BDX) has received 510(k) clearance from the FDA for its BD Vaginal Panel on the BD COR™ System, a diagnostic test that detects the three most common causes of vaginitis using a single swab. This test improves detection accuracy for conditions like bacterial vaginosis and vulvovaginal candidiasis, ensuring proper treatment and helping reduce misdiagnoses. The BD Vaginal Panel is the first high-throughput version of its kind, further enhancing BD's commitment to women's health diagnostics. The BD COR™ System allows high-volume testing, significantly improving laboratory efficiency and patient management.
BD (Becton, Dickinson and Company) (NYSE: BDX) will present at the Barclays Global Healthcare Conference on March 15, 2023, at 9:00 am Eastern Time. The live webcast can be accessed via the BD investor relations website, with a replay available afterward. BD is a leading global medical technology company focused on improving health through innovative technologies and services. With a workforce of 77,000, BD collaborates globally to tackle critical health issues, enhance clinical processes, and foster efficient care delivery. For more information about BD, visit bd.com.
BD (Becton, Dickinson and Company), a top medical technology firm, will present at the Cowen 43rd Annual Healthcare Conference on March 6, 2023, at 9:50 AM Eastern Time. Investors can access the live webcast on BD's investor relations website. A replay will be available after the event. BD focuses on advancing healthcare with innovative technologies and services, supporting healthcare professionals in improving patient outcomes. With a global workforce of 77,000, BD addresses key health challenges through collaborations worldwide. For more details, visit bd.com.
BD (NYSE: BDX) has received FDA approval for its Onclarity™ HPV Assay, designed for use with the ThinPrep® Pap Test. This assay is uniquely capable of individually identifying a broader range of HPV types, including the high-risk HPV31, which significantly enhances the ability to assess cervical cancer risk. The Onclarity™ HPV Assay’s approval supports BD's strategy to grow in the molecular diagnostics market. It detects 14 high-risk HPV types, providing crucial insights for clinical decision-making. The assay is validated through a large real-world study, improving both screening efficacy and women’s health management.
BD (NYSE: BDX) announced FDA Emergency Use Authorization for a new molecular diagnostic test that identifies SARS-CoV-2, Influenza A+B, and Respiratory Syncytial Virus (RSV). This test, designed for the BD MAX™ System, allows for rapid diagnosis using a single nasal or nasopharyngeal swab, with results available in as little as two hours. It aims to streamline testing during respiratory virus seasons and enhance clinical treatment strategies. The BD MAX™ System is already widely utilized across hospitals and laboratories, capable of analyzing hundreds of samples daily.
BD (NYSE: BDX) announced the launch of the BD Rhapsody™ HT Xpress System designed for single-cell multiomics analysis, enabling researchers to conduct high-throughput studies with improved sample integrity. This new system can analyze up to eight times more cells than previous models, allowing simultaneous analysis of various cell types like stem and cancer cells. The system will be showcased at the AGBT General Meeting from February 6-9, 2023, in Hollywood, Florida. Additionally, BD is introducing the BD Rhapsody™ Mouse TCR/BCR Multiomic Assay and BD® Flex Single-Cell Multiplexing Kits to enhance data collection capabilities.
FAQ
What is the current stock price of Becton, Dickinson and Co. (BDX)?
What is the market cap of Becton, Dickinson and Co. (BDX)?
What does Becton, Dickinson and Company (BD) specialize in?
What are BD's main business segments?
What recent projects has BD undertaken?
How much of BD's revenue comes from international markets?
What significant acquisition has BD announced recently?
How many employees does BD have?
Where can I find more information about BD's financial performance?
What is the significance of the BD FACSDiscover™ S8 Cell Sorters?
Which regulatory body recently issued a safety communication regarding syringes?
What is BD's approach to sustainability?
